;PMID: 8513433
;source_file_933.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..144] = [t:52..144]
;2)section:[e:148..168] = [t:148..168]
;3)section:[e:172..286] = [t:172..286]
;4)sentence:[e:290..412] = [t:290..412]
;5)sentence:[e:413..730] = [t:413..730]
;6)sentence:[e:731..912] = [t:731..912]
;7)sentence:[e:914..988] = [t:914..988]
;8)sentence:[e:989..1239] = [t:989..1239]
;9)sentence:[e:1240..1414] = [t:1240..1414]
;10)sentence:[e:1415..1673] = [t:1415..1673]
;11)section:[e:1677..1721] = [t:1677..1721]

;section 0 Span:0..46
;Can J Physiol Pharmacol. 1993 Jan;71(1):48-53.
(SEC
  (FRAG (MD:[0..3] Can) (NNP:[4..5] J) (NNP:[6..13] Physiol)
        (NNP:[14..23] Pharmacol) (.:[23..24] .) (CD:[25..29] 1993)
        (CC:[30..37] Jan;71-LRB-) (CD:[37..38] 1) (-RRB-:[38..39] -RRB-)
        (CD:[39..42] :48) (::[42..43] -) (CD:[43..45] 53) (.:[45..46] .)))

;sentence 1 Span:52..144
;General anesthetics inhibit cytochrome P450 monooxygenases and arachidonic
;acid  metabolism.
;[80..110]:substance:"cytochrome P450 monooxygenases"
;[115..131]:substance:"arachidonic acid"
(SENT
  (S-HLN
    (NP-SBJ (JJ:[52..59] General) (NNS:[60..71] anesthetics))
    (VP (VBP:[72..79] inhibit)
      (NP
        (NP
          (NML (NN:[80..90] cytochrome) (NN:[91..95] P450))
          (NNS:[96..110] monooxygenases))
        (CC:[111..114] and)
        (NP
          (NML (JJ:[115..126] arachidonic) (NN:[127..131] acid))
          (NN:[133..143] metabolism))))
    (.:[143..144] .)))

;section 2 Span:148..168
;LaBella FS, Queen G.
(SEC
  (FRAG (NNP:[148..155] LaBella) (NNP:[156..158] FS) (,:[158..159] ,)
        (NNP:[160..165] Queen) (NNP:[166..168] G.)))

;section 3 Span:172..286
;Department of Pharmacology and Therapeutics, University of Manitoba, Faculty
;of  Medicine, Winnipeg, Man., Canada.
(SEC
  (FRAG (NNP:[172..182] Department) (IN:[183..185] of)
        (NNP:[186..198] Pharmacology) (CC:[199..202] and)
        (NNP:[203..215] Therapeutics) (,:[215..216] ,)
        (NNP:[217..227] University) (IN:[228..230] of) (NNP:[231..239] Manitoba)
        (,:[239..240] ,) (NNP:[241..248] Faculty) (IN:[249..251] of)
        (NNP:[253..261] Medicine) (,:[261..262] ,) (NNP:[263..271] Winnipeg)
        (,:[271..272] ,) (NNP:[273..277] Man.) (,:[277..278] ,)
        (NNP:[279..285] Canada) (.:[285..286] .)))

;sentence 4 Span:290..412
;Identification of a specific biomolecular target appropriately sensitive to a
; wide array of anesthetics has been elusive.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[290..304] Identification))
      (PP (IN:[305..307] of)
        (NP
          (NP (DT:[308..309] a) (JJ:[310..318] specific)
              (JJ:[319..331] biomolecular) (NN:[332..338] target))
          (ADJP (RB:[339..352] appropriately) (JJ:[353..362] sensitive)
            (PP (TO:[363..365] to)
              (NP
                (NP (DT:[366..367] a) (JJ:[369..373] wide) (NN:[374..379] array))
                (PP (IN:[380..382] of)
                  (NP (NNS:[383..394] anesthetics)))))))))
    (VP (VBZ:[395..398] has)
      (VP (VBN:[399..403] been)
        (ADJP-PRD (JJ:[404..411] elusive))))
    (.:[411..412] .)))

;sentence 5 Span:413..730
;At concentrations close to their  respective ED50's for anesthesia in man or
;other species, 18 compounds,  differing in potencies up to 66,000 fold,
;inhibited cytochrome P450 mediated  metabolism of aminopyrine, a synthetic
;substrate, and arachidonic acid (AA), an  endogenous substrate, in isolated
;liver microsomes.
;[458..464]:quantitative-name:"ED50's"
;[508..517]:substance:"compounds"
;[543..560]:quantitative-value:"up to 66,000 fold"
;[572..587]:cyp450:"cytochrome P450"
;[612..623]:substance:"aminopyrine"
;[637..646]:substance:"substrate"
;[652..668]:substance:"arachidonic acid"
;[670..672]:substance:"AA"
;[690..699]:substance:"substrate"
(SENT
  (S
    (PP (IN:[413..415] At)
      (NP
        (NP (NNS:[416..430] concentrations))
        (ADJP (JJ:[431..436] close)
          (PP (TO:[437..439] to)
            (NP
              (NP (PRP$:[440..445] their) (JJ:[447..457] respective)
                 (NN:[458..462] ED50) (POS:[462..464] 's))
              (PP (IN:[465..468] for)
                (NP
                  (NP (NN:[469..479] anesthesia))
                  (PP-LOC (IN:[480..482] in)
                    (NP
                      (NP (NN:[483..486] man))
                      (CC:[487..489] or)
                      (NP (JJ:[490..495] other) (NNS:[496..503] species)))))))))))
    (,:[503..504] ,)
    (NP-SBJ
      (NP (CD:[505..507] 18) (NNS:[508..517] compounds))
      (,:[517..518] ,)
      (VP (VBG:[520..529] differing)
        (PP (IN:[530..532] in)
          (NP (NNS:[533..542] potencies)))
        (ADVP-EXT
          (QP (IN:[543..545] up) (TO:[546..548] to) (CD:[549..555] 66,000))
          (RB:[556..560] fold))))
    (,:[560..561] ,)
    (VP (VBD:[562..571] inhibited)
      (NP
        (NP
          (ADJP
            (NML (NN:[572..582] cytochrome) (NN:[583..587] P450))
            (VBN:[588..596] mediated))
          (NN:[598..608] metabolism))
        (PP (IN:[609..611] of)
          (NP
            (NP
              (NP (NN:[612..623] aminopyrine))
              (,:[623..624] ,)
              (NP (DT:[625..626] a) (JJ:[627..636] synthetic)
                  (NN:[637..646] substrate)))
            (,:[646..647] ,) (CC:[648..651] and)
            (NP
              (NP
                (NP (JJ:[652..663] arachidonic) (NN:[664..668] acid))
                (NP (-LRB-:[669..670] -LRB-) (NN:[670..672] AA)
                    (-RRB-:[672..673] -RRB-)))
              (,:[673..674] ,)
              (NP (DT:[675..677] an) (JJ:[679..689] endogenous)
                  (NN:[690..699] substrate))))))
      (,:[699..700] ,)
      (PP-LOC (IN:[701..703] in)
        (NP (VBN:[704..712] isolated) (NN:[713..718] liver)
            (NNS:[719..729] microsomes))))
    (.:[729..730] .)))

;sentence 6 Span:731..912
;There was a highly  significant correlation for both substrates between the
;absolute concentrations  required for anesthesia (EC50) and for inhibition of
;P450 activity (Ki or IC50).
;[784..794]:substance:"substrates"
;[857..861]:quantitative-name:"EC50"
;[885..889]:cyp450:"P450"
;[900..902]:quantitative-name:"Ki"
;[906..910]:quantitative-name:"IC50"
(SENT
  (S
    (NP-SBJ (EX:[731..736] There))
    (VP (VBD:[737..740] was)
      (NP-PRD
        (NP (DT:[741..742] a)
          (ADJP (RB:[743..749] highly) (JJ:[751..762] significant))
          (NN:[763..774] correlation))
        (PP (IN:[775..778] for)
          (NP (DT:[779..783] both) (NNS:[784..794] substrates)))
        (PP (IN:[795..802] between)
          (NP
            (NP (DT:[803..806] the) (JJ:[807..815] absolute)
                (NNS:[816..830] concentrations))
            (VP (VBN:[832..840] required)
              (NP (-NONE-:[840..840] *))
              (PP
                (PP (IN:[841..844] for)
                  (NP
                    (NP (NN:[845..855] anesthesia))
                    (PRN (-LRB-:[856..857] -LRB-)
                      (NP (NN:[857..861] EC50))
                      (-RRB-:[861..862] -RRB-))))
                (CC:[863..866] and)
                (PP (IN:[867..870] for)
                  (NP
                    (NP (NN:[871..881] inhibition))
                    (PP (IN:[882..884] of)
                      (NP (NN:[885..889] P450) (NN:[890..898] activity))))))
              (PRN (-LRB-:[899..900] -LRB-)
                (NP (NN:[900..902] Ki) (CC:[903..905] or) (NN:[906..910] IC50))
                (-RRB-:[910..911] -RRB-)))))))
    (.:[911..912] .)))

;sentence 7 Span:914..988
;The mean Ki/EC50 ratio was 0.97 for inhibition of aminopyrine demethylase.
;[923..930]:quantitative-name:"Ki/EC50"
;[941..945]:quantitative-value:"0.97"
;[964..987]:substance:"aminopyrine demethylase"
(SENT
  (S
    (NP-SBJ (DT:[914..917] The) (JJ:[918..922] mean)
      (NML (NN:[923..925] Ki) (SYM:[925..926] /) (NN:[926..930] EC50))
      (NN:[931..936] ratio))
    (VP (VBD:[937..940] was)
      (NP-PRD
        (NP (CD:[941..945] 0.97))
        (PP (IN:[946..949] for)
          (NP
            (NP (NN:[950..960] inhibition))
            (PP (IN:[961..963] of)
              (NP (NN:[964..975] aminopyrine) (NN:[976..987] demethylase)))))))
    (.:[987..988] .)))

;sentence 8 Span:989..1239
;The  mean IC50/EC50 ratios were 0.42 and 0.64 for inhibition of two
;AA-derived  products and 2.8 for a third; a mean ratio of 1.4 for inhibition
;of overall AA  metabolism suggests interaction of general anesthetics with a
;composite of P450  isozymes.
;[999..1008]:quantitative-name:"IC50/EC50"
;[1021..1025]:quantitative-value:"0.42"
;[1030..1034]:quantitative-value:"0.64"
;[1057..1059]:substance:"AA"
;[1069..1077]:substance:"products"
;[1082..1085]:quantitative-value:"2.8"
;[1115..1118]:quantitative-value:"1.4"
;[1145..1147]:substance:"AA"
;[1192..1203]:substance:"anesthetics"
;[1224..1238]:cyp450:"P450  isozymes"
(SENT
  (S
    (S
      (NP-SBJ (DT:[989..992] The) (JJ:[994..998] mean)
        (NML (NN:[999..1003] IC50) (SYM:[1003..1004] /) (NN:[1004..1008] EC50))
        (NNS:[1009..1015] ratios))
      (VP (VBD:[1016..1020] were)
        (NP-PRD
          (NP
            (NP (CD:[1021..1025] 0.42) (CC:[1026..1029] and)
                (CD:[1030..1034] 0.64))
            (PP (IN:[1035..1038] for)
              (NP
                (NP (NN:[1039..1049] inhibition))
                (PP (IN:[1050..1052] of)
                  (NP (CD:[1053..1056] two)
                    (ADJP (NN:[1057..1059] AA) (HYPH:[1059..1060] -)
                          (VBN:[1060..1067] derived))
                    (NNS:[1069..1077] products))))))
          (CC:[1078..1081] and)
          (NP
            (NP (CD:[1082..1085] 2.8))
            (PP (IN:[1086..1089] for)
              (NP (DT:[1090..1091] a) (JJ:[1092..1097] third)))))))
    (::[1097..1098] ;)
    (S
      (NP-SBJ
        (NP (DT:[1099..1100] a) (JJ:[1101..1105] mean) (NN:[1106..1111] ratio))
        (PP (IN:[1112..1114] of)
          (NP (CD:[1115..1118] 1.4)))
        (PP (IN:[1119..1122] for)
          (NP
            (NP (NN:[1123..1133] inhibition))
            (PP (IN:[1134..1136] of)
              (NP (JJ:[1137..1144] overall) (NN:[1145..1147] AA)
                  (NN:[1149..1159] metabolism))))))
      (VP (VBZ:[1160..1168] suggests)
        (NP
          (NP (NN:[1169..1180] interaction))
          (PP (IN:[1181..1183] of)
            (NP (JJ:[1184..1191] general) (NNS:[1192..1203] anesthetics)))
          (PP (IN:[1204..1208] with)
            (NP
              (NP (DT:[1209..1210] a) (NN:[1211..1220] composite))
              (PP (IN:[1221..1223] of)
                (NP (NN:[1224..1228] P450) (NNS:[1230..1238] isozymes))))))))
    (.:[1238..1239] .)))

;sentence 9 Span:1240..1414
;The universal cytochrome P450 monooxygenases, in conjunction with  other
;lipid oxygenases (cyclooxygenases and lipoxygenases) participate in the 
;second messenger AA cascade.
;[1254..1284]:substance:"cytochrome P450 monooxygenases"
;[1313..1329]:substance:"lipid oxygenases"
;[1331..1346]:substance:"cyclooxygenases"
;[1351..1364]:substance:"lipoxygenases"
;[1403..1405]:substance:"AA"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1240..1243] The) (JJ:[1244..1253] universal)
        
        (NML (NN:[1254..1264] cytochrome) (NN:[1265..1269] P450))
        (NNS:[1270..1284] monooxygenases))
      (,:[1284..1285] ,)
      (PP (IN:[1286..1288] in)
        (NP
          (NP (NN:[1289..1300] conjunction))
          (PP (IN:[1301..1305] with)
            (NP
              (NP (JJ:[1307..1312] other)
                 (NN:[1313..1318] lipid) (NNS:[1319..1329] oxygenases))
              (NP (-LRB-:[1330..1331] -LRB-) (NNS:[1331..1346] cyclooxygenases)
                  (CC:[1347..1350] and) (NNS:[1351..1364] lipoxygenases)
                  (-RRB-:[1364..1365] -RRB-)))))))
    (VP (VBP:[1366..1377] participate)
      (PP-CLR (IN:[1378..1380] in)
        (NP (DT:[1381..1384] the)
          (NML (JJ:[1386..1392] second) (NN:[1393..1402] messenger))
          (NN:[1403..1405] AA) (NN:[1406..1413] cascade))))
    (.:[1413..1414] .)))

;sentence 10 Span:1415..1673
;In nerve cells the sensitivity of these enzymes to  hydrophobic
;neurodepressant drugs may underlie the state of general anesthesia: 
;reversible disruption of intracellular and intercellular signalling without 
;impairment of enzymes vital to cell respiration.
;[1455..1462]:substance:"enzymes"
;[1479..1500]:substance:"neurodepressant drugs"
;[1639..1646]:substance:"enzymes"
(SENT
  (S
    (PP-LOC
      (NP (IN:[1415..1417] In) (NN:[1418..1423] nerve) (NNS:[1424..1429] cells)))
    (NP-SBJ
      (NP (DT:[1430..1433] the) (NN:[1434..1445] sensitivity))
      (PP (IN:[1446..1448] of)
        (NP (DT:[1449..1454] these) (NNS:[1455..1462] enzymes)))
      (PP (TO:[1463..1465] to)
        (NP (JJ:[1467..1478] hydrophobic)
           (JJ:[1479..1494] neurodepressant) (NNS:[1495..1500] drugs))))
    (VP (MD:[1501..1504] may)
      (VP (VB:[1505..1513] underlie)
        (NP
          (NP
            (NP (DT:[1514..1517] the) (NN:[1518..1523] state))
            (PP (IN:[1524..1526] of)
              (NP (JJ:[1527..1534] general) (NN:[1535..1545] anesthesia))))
          (::[1545..1546] :)
          (NP
            (NP (JJ:[1548..1558] reversible) (NN:[1559..1569] disruption))
            (PP (IN:[1570..1572] of)
              (NP
                (NP (JJ:[1573..1586] intracellular)
                  (NML-1 (-NONE-:[1586..1586] *P*)))
                (CC:[1587..1590] and)
                (NP (JJ:[1591..1604] intercellular)
                  (NML-1 (NN:[1605..1615] signalling)))))
            (PP (IN:[1616..1623] without)
              (NP
                (NP (NN:[1625..1635] impairment))
                (PP (IN:[1636..1638] of)
                  (NP
                    (NP (NNS:[1639..1646] enzymes))
                    (ADJP (JJ:[1647..1652] vital)
                      (PP (TO:[1653..1655] to)
                        (NP (NN:[1656..1660] cell) (NN:[1661..1672] respiration))))))))))))
    (.:[1672..1673] .)))

;section 11 Span:1677..1721
;PMID: 8513433 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1677..1681] PMID) (::[1681..1682] :) (CD:[1683..1690] 8513433)
        (NN:[1691..1692] -LSB-) (NNP:[1692..1698] PubMed) (::[1699..1700] -)
        (NN:[1701..1708] indexed) (IN:[1709..1712] for)
        (NNP:[1713..1721] MEDLINE-RSB-)))
